About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Oncology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Primary Care
Psychiatry
Pulmonology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refractory Multiple Myeloma Treatment
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Meletios Dimopoulos
October 17, 2019
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
Emory Global Perioperative Health Alliance
Emory Global Perioperative Alliance virtual Symposium: "Interprofessional …
Sat, Mar 6, 2021
05:09
Association of Community Cancer Centers (ACCC)
72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …
Feat.
K. Maples
14:16
2nd SOHO Italian Conference
2020 SOHO Update on MM: What Is the Role of Transplant and MRD? How Do Tri…
Feat.
K. Anderson
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Achi…
Feat.
T. Martin
26:18
Morie Gertz
Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Sequen…
08:15
2018 Pan Pacific Lymphoma Conference
Evolution of Myeloma Induction Regimens
Feat.
S. Holstein
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases
MM - Overview of Trials Presented at ASH 2018
Feat.
A. Abdallah
15:22
SOHO Italy 1st School of Multiple Myeloma
Dissecting Daratumumab Mechanisms of Resistance in MM: Identification of N…
Feat.
M. Claudio Da Via
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology
Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the My…
Feat.
J. Berdeja
12:03
Andrew Cowan
BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...
09:50
Nina Shah
Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Mainten…
19:41
Peter Voorhees
Approach to the Patient with Refractory & Multiple Relapsed Multiple Myelo…
06:12
Indy Hematology Review
Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...
Feat.
K. Anderson
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, an…
Feat.
S. Jagannath
15:02
Krina Patel
Clinical Trials in Myeloma in 2018
15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Mana…
Feat.
S. Lonial
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to...
Feat.
A. Rosko
15:11
Ajay Nooka
Early Relapse: Choosing Among Different Second Line Regimens in Myeloma
08:25
Cristina Gasparetto
2020 ASCO Update on Selinexor in R/R Multiple Myeloma: What Is the Effec...
15:52
Thomas Martin
ASH 2020 IKEMA Trial Update on Isatuximab in R/R MM: Should We Consider Is…
19:43
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Myeloma: KRd vs. VRd for Initial Therapy of Newly Diag…
Feat.
R. Vij